Trial Profile
A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Eflornithine (Primary) ; Ceritinib; Dasatinib; Sorafenib; Vorinostat
- Indications Neuroblastoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PEDS-PLAN
- 26 Sep 2023 Planned End Date changed from 1 Sep 2032 to 1 Sep 2035.
- 26 Sep 2023 Planned primary completion date changed from 1 Sep 2027 to 1 Sep 2030.
- 23 Sep 2020 Planned End Date changed from 1 Sep 2026 to 1 Sep 2032.